Codi QR

HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia

Objective: To report safety and early pharmacodynamic results from a first-in-human trial of intravitreal (IVT) anti-semaphorin 3A antibody in participants with diabetic macular ischemia (DMI). Design: HORNBILL, a phase I/IIa study of BI 764524, comprised a nonrandomized, open-label, uncontrolled, s...

Descripció completa

Guardat en:
Autors principals: Quan Dong Nguyen, MD, MSc, Chirag Jhaveri, MD, Maged Habib, MD, Yasir J. Sepah, MBBS, Khaled Nassar, MD, PhD, Bartlomiej Krawczyk, PhD, Gudrun Simons, PhD, Andrea Giani, MD, Elizabeth Pearce, PhD, Martin Gliem, MD, Mohamed Ahmed, MBBCh, MD, Sobha Sivaprasad, DM
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2025-09-01
Col·lecció:Ophthalmology Science
Matèries:
Diabetic retinopathy
Sema3A
First-in-human
Retinal nonperfusion
Ischemia
Accés en línia:http://www.sciencedirect.com/science/article/pii/S266691452500079X
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars